Actinium Pharmaceuticals, Inc. (ATNM)Healthcare | Biotechnology | New York, United States | NYSE American
0.91 USD
-0.03
(-2.688%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:31 a.m. EDT
Actinium Pharmaceuticals is a distressed biotech play with no dividend and a fundamentally broken business model. The company is burning massive cash, reporting negative operating margins of nearly -283%, and has a trailing P/E that implies negative earnings. The stock has suffered a catastrophic 97% decline over the last nine years, with the most recent annual drop being a staggering 79%. While analysts have set a lofty target price of $9.00, this is disconnected from the reality of a company with negligible revenue ($90k) and a crumbling balance sheet. The recent news regarding listing compliance issues further underscores the precarious nature of the business. With no institutional support in the options chain and a statistical model predicting a slight further decline, there is no safe entry point here. This is a speculative gamble on a clinical trial success rather than an investment in a viable company. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.098852 |
| AutoETS | 0.105685 |
| AutoARIMA | 0.106591 |
| MSTL | 0.107772 |
| MSTL_126 | 0.107792 |
| MSTL_97 | 0.124541 |
| MSTL_97_126 | 0.169147 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.377 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 65.929 |
| Revenue per Share | 0.003 |
| Market Cap | 28,394,368 |
| Forward P/E | -2.59 |
| Beta | -0.02 |
| Website | https://www.actiniumpharma.com |
As of July 11, 2026, 3:31 a.m. EDT: Options activity is extremely thin with negligible open interest across all expirations. Implied volatility is effectively zero for most strikes, indicating a lack of speculative positioning. There is a tiny amount of put volume at the nearest expiration, suggesting minimal hedging or bearish bets, but the overall market is inactive and uninterested in this ticker.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.40764332 |
| Address1 | 100 Park Avenue |
| Address2 | 23rd Floor |
| All Time High | 450.0 |
| All Time Low | 0.92 |
| Ask | 0.0 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 109,330 |
| Average Daily Volume3 Month | 177,508 |
| Average Volume | 177,508 |
| Average Volume10Days | 109,330 |
| Beta | -0.015 |
| Bid | 0.0 |
| Bid Size | 100 |
| Book Value | 0.073 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.905 |
| Current Ratio | 5.887 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.9705 |
| Day Low | 0.9001 |
| Debt To Equity | 65.929 |
| Display Name | Actinium Pharmaceuticals |
| Dividend Date | 1,597,104,000 |
| Earnings Timestamp End | 1,754,683,200 |
| Earnings Timestamp Start | 1,754,337,600 |
| Ebitda | -25,347,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.482 |
| Enterprise To Revenue | -135.763 |
| Enterprise Value | -12,218,633 |
| Eps Current Year | -0.91 |
| Eps Forward | -0.35 |
| Eps Trailing Twelve Months | -0.76 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.10924 |
| Fifty Day Average Change | -0.20424008 |
| Fifty Day Average Change Percent | -0.18412614 |
| Fifty Two Week Change Percent | -40.76433 |
| Fifty Two Week High | 1.89 |
| Fifty Two Week High Change | -0.985 |
| Fifty Two Week High Change Percent | -0.52116406 |
| Fifty Two Week Low | 0.9001 |
| Fifty Two Week Low Change | 0.0048999786 |
| Fifty Two Week Low Change Percent | 0.005443816 |
| Fifty Two Week Range | 0.9001 - 1.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,356,618,600,000 |
| Float Shares | 31,187,996 |
| Forward Eps | -0.35 |
| Forward P E | -2.5857143 |
| Free Cashflow | -14,791,000 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 90,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.023459999 |
| Held Percent Institutions | 0.20607 |
| Implied Shares Outstanding | 31,374,994 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,597,104,000 |
| Last Split Factor | 1:30 |
| Long Business Summary | Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York. |
| Long Name | Actinium Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 28,394,368 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_7845787 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -23,471,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 28,394,369 |
| Number Of Analyst Opinions | 4 |
| Open | 0.9238 |
| Operating Cashflow | -22,876,000 |
| Operating Margins | -283.46667 |
| Payout Ratio | 0.0 |
| Phone | 646 677 3870 |
| Previous Close | 0.93 |
| Price Eps Current Year | -0.9945054 |
| Price Hint | 4 |
| Price To Book | 12.39726 |
| Price To Sales Trailing12 Months | 315.49298 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.733 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.025 |
| Regular Market Change Percent | -2.68818 |
| Regular Market Day High | 0.9705 |
| Regular Market Day Low | 0.9001 |
| Regular Market Day Range | 0.9001 - 0.9705 |
| Regular Market Open | 0.9238 |
| Regular Market Previous Close | 0.93 |
| Regular Market Price | 0.905 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 95,795 |
| Return On Assets | -0.27953 |
| Return On Equity | -1.67662 |
| Revenue Per Share | 0.003 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 31,374,994 |
| Shares Percent Shares Out | 0.0299 |
| Shares Short | 936,708 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,082,196 |
| Short Name | Actinium Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.03 |
| Short Ratio | 6.2 |
| Source Interval | 15 |
| State | NY |
| Symbol | ATNM |
| Target High Price | 9.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 5.0 |
| Target Median Price | 4.5 |
| Total Cash | 42,132,000 |
| Total Cash Per Share | 1.343 |
| Total Debt | 1,519,000 |
| Total Revenue | 90,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.76 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.270185 |
| Two Hundred Day Average Change | -0.36518502 |
| Two Hundred Day Average Change Percent | -0.2875054 |
| Type Disp | Equity |
| Volume | 95,795 |
| Website | https://www.actiniumpharma.com |
| Zip | 10,017 |